Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials

Altomonte, 2013, Clinical experience with ipilimumab 10mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme, J. Exp. Clin. Cancer Res., 32, 82, 10.1186/1756-9966-32-82 Ansell, 2009, Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma, Clin. Cancer Res., 15, 6446, 10.1158/1078-0432.CCR-09-1339 Ansell, 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma, N. Engl. J. Med., 372, 311, 10.1056/NEJMoa1411087 Antonia, 2016, Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study, Lancet Oncol., 17, 299, 10.1016/S1470-2045(15)00544-6 Armand, 2013, Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial, J. Clin. Oncol., 31, 4199, 10.1200/JCO.2012.48.3685 Balar, 2017, Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial, Lancet, 389, 67, 10.1016/S0140-6736(16)32455-2 Bashey, 2009, CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation, Blood, 113, 1581, 10.1182/blood-2008-07-168468 Berger, 2008, Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies, Clin. Cancer Res., 14, 3044, 10.1158/1078-0432.CCR-07-4079 Bertrand, 2015, Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis, BMC Med., 13, 211, 10.1186/s12916-015-0455-8 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N. Engl. J. Med., 373, 1627, 10.1056/NEJMoa1507643 Brahmer, 2010, Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates, J. Clin. Oncol., 28, 3167, 10.1200/JCO.2009.26.7609 Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N. Engl. J. Med., 366, 2455, 10.1056/NEJMoa1200694 Calabro, 2013, Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial, Lancet Oncol., 14, 1104, 10.1016/S1470-2045(13)70381-4 Camacho, 2009, Phase I/II trial of tremelimumab in patients with metastatic melanoma, J. Clin. Oncol., 27, 1075, 10.1200/JCO.2008.19.2435 Carthon, 2010, Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial, Clin. Cancer Res., 16, 2861, 10.1158/1078-0432.CCR-10-0569 Chen, 2015, A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors, Ann. Oncol., 26, 1824, 10.1093/annonc/mdv182 Chiarion Sileni, 2014, Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme, J. Exp. Clin. Cancer Res., 33, 30, 10.1186/1756-9966-33-30 Chung, 2010, Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer, J. Clin. Oncol., 28, 3485, 10.1200/JCO.2010.28.3994 Danielli, 2012, Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy, Cancer Immunol. Immunother., 61, 41, 10.1007/s00262-011-1089-0 Davids, 2016, Ipilimumab for patients with relapse after allogeneic transplantation, N. Engl. J. Med., 375, 143, 10.1056/NEJMoa1601202 Di Giacomo, 2011, Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy), Cancer Immunol. Immunother., 60, 467, 10.1007/s00262-010-0958-2 Downey, 2007, Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade, Clin. Cancer Res., 13, 6681, 10.1158/1078-0432.CCR-07-0187 Eggermont, 2015, Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial, Lancet Oncol., 16, 522, 10.1016/S1470-2045(15)70122-1 Eggermont, 2016, Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy, N. Engl. J. Med., 375, 1845, 10.1056/NEJMoa1611299 Eigentler, 2014, Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions, J. Immunother., 37, 374, 10.1097/CJI.0000000000000046 Fehrenbacher, 2016, Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, Lancet, 387, 1837, 10.1016/S0140-6736(16)00587-0 Ferris, 2016, Nivolumab for recurrent squamous-cell carcinoma of the head and neck, N. Engl. J. Med., 10.1056/NEJMoa1602252 Floyd, 2016, First report of parkinsonism associated with Indoximod, an immune-modulating agent, J. Global Oncol., 10.1200/JGO.2016.007492 Garon, 2015, Pembrolizumab for the treatment of non-small-cell lung cancer, N. Engl. J. Med., 372, 2018, 10.1056/NEJMoa1501824 Gettinger, 2015, Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer, J. Clin. Oncol., 33, 2004, 10.1200/JCO.2014.58.3708 Hamid, 2013, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N. Engl. J. Med., 369, 134, 10.1056/NEJMoa1305133 Herbst, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, 387, 1540, 10.1016/S0140-6736(15)01281-7 Hersh, 2011, A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma, Invest. New Drugs, 29, 489, 10.1007/s10637-009-9376-8 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N. Engl. J. Med., 363, 711, 10.1056/NEJMoa1003466 Hodi, 2014, Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial, JAMA, 312, 1744, 10.1001/jama.2014.13943 Kaufman, 2016, Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial, Lancet Oncol., 17, 1374, 10.1016/S1470-2045(16)30364-3 Keir, 2008, PD-1 and its ligands in tolerance and immunity, Annu. Rev. Immunol., 26, 677, 10.1146/annurev.immunol.26.021607.090331 Kirkwood, 2008, Next generation of immunotherapy for melanoma, J. Clin. Oncol., 26, 3445, 10.1200/JCO.2007.14.6423 Kirkwood, 2010, Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma, Clin. Cancer Res., 16, 1042, 10.1158/1078-0432.CCR-09-2033 Kwon, 2014, Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial, Lancet Oncol., 15, 700, 10.1016/S1470-2045(14)70189-5 Larkin, 2015, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N. Engl. J. Med., 373, 23, 10.1056/NEJMoa1504030 Le, 2013, Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer, J. Immunother., 36, 382, 10.1097/CJI.0b013e31829fb7a2 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N. Engl. J. Med., 372, 2509, 10.1056/NEJMoa1500596 Luke, 2013, Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience, Cancer, 119, 3687, 10.1002/cncr.28282 Margolin, 2012, Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial, Lancet Oncol., 13, 459, 10.1016/S1470-2045(12)70090-6 Massard, 2016, Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer, J. Clin. Oncol., 34, 3119, 10.1200/JCO.2016.67.9761 McDermott, 2015, Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab, J. Clin. Oncol., 33, 2013, 10.1200/JCO.2014.58.1041 McDermott, 2016, Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase ia study, J. Clin. Oncol., 34, 833, 10.1200/JCO.2015.63.7421 Motzer, 2015, Nivolumab versus everolimus in advanced renal-cell carcinoma, N. Engl. J. Med., 373, 1803, 10.1056/NEJMoa1510665 Nghiem, 2016, PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma, N. Engl. J. Med., 374, 2542, 10.1056/NEJMoa1603702 O'Day, 2010, Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study, Ann. Oncol., 21, 1712, 10.1093/annonc/mdq013 Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat. Rev. Cancer, 12, 252, 10.1038/nrc3239 Postow, 2013, Ipilimumab for patients with advanced mucosal melanoma, Oncologist, 18, 726, 10.1634/theoncologist.2012-0464 Postow, 2015, Immune checkpoint blockade in cancer therapy, J. Clin. Oncol., 33, 1974, 10.1200/JCO.2014.59.4358 Postow, 2015, Nivolumab and ipilimumab versus ipilimumab in untreated melanoma, N. Engl. J. Med., 372, 2006, 10.1056/NEJMoa1414428 Ralph, 2010, Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma, Clin. Cancer Res., 16, 1662, 10.1158/1078-0432.CCR-09-2870 Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N. Engl. J. Med., 375, 1823, 10.1056/NEJMoa1606774 Ribas, 2012, Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion, J. Transl. Med., 10, 236, 10.1186/1479-5876-10-236 Ribas, 2013, Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma, J. Clin. Oncol., 31, 616, 10.1200/JCO.2012.44.6112 Ribas, 2015, Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, Lancet Oncol., 16, 908, 10.1016/S1470-2045(15)00083-2 Ribas, 2012, Tumor immunotherapy directed at PD-1, N. Engl. J. Med., 366, 2517, 10.1056/NEJMe1205943 Rizvi, 2015, Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial, Lancet Oncol., 16, 257, 10.1016/S1470-2045(15)70054-9 Robert, 2013, Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control, Clin. Cancer Res., 19, 2232, 10.1158/1078-0432.CCR-12-3080 Robert, 2014, Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial, Lancet, 384, 1109, 10.1016/S0140-6736(14)60958-2 Robert, 2015, Pembrolizumab versus ipilimumab in advanced melanoma, N. Engl. J. Med., 372, 2521, 10.1056/NEJMoa1503093 Robert, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, N. Engl. J. Med., 372, 320, 10.1056/NEJMoa1412082 Rosenberg, 2016, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, Lancet, 387, 1909, 10.1016/S0140-6736(16)00561-4 Royal, 2010, Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma, J. Immunother., 33, 828, 10.1097/CJI.0b013e3181eec14c Sangro, 2013, A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C, J. Hepatol., 59, 81, 10.1016/j.jhep.2013.02.022 Seiwert, 2016, Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial, Lancet Oncol., 17, 956, 10.1016/S1470-2045(16)30066-3 Slovin, 2013, Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study, Ann. Oncol., 24, 1813, 10.1093/annonc/mdt107 Small, 2007, A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer, Clin. Cancer Res., 13, 1810, 10.1158/1078-0432.CCR-06-2318 Spellman, 2016, Immunotherapy for breast cancer: past, present, and future, Cancer Metastasis Rev., 10.1007/s10555-016-9654-9 Weber, 2008, Phase I/II study of ipilimumab for patients with metastatic melanoma, J. Clin. Oncol., 26, 5950, 10.1200/JCO.2008.16.1927 Weber, 2009, A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma, Clin. Cancer Res., 15, 5591, 10.1158/1078-0432.CCR-09-1024 Weber, 2013, Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma, Cancer, 119, 1675, 10.1002/cncr.27969 Weber, 2013, Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma, J. Clin. Oncol., 31, 4311, 10.1200/JCO.2013.51.4802 Weber, 2015, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol., 16, 375, 10.1016/S1470-2045(15)70076-8 Wolchok, 2008, The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation, Oncologist, 13, 2, 10.1634/theoncologist.13-S4-2 Wolchok, 2010, Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study, Lancet Oncol., 11, 155, 10.1016/S1470-2045(09)70334-1 Yang, 2007, Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis, J. Immunother., 30, 825, 10.1097/CJI.0b013e318156e47e